Business Wire Feed
Samsung Bioepis Announces Approval of Ustekinumab Biosimilar in Japan
Ustekinumab BS Subcutaneous Injection 45mg Syringes 'NIPRO' has been granted marketing approval in Japan First marketing approval under the partnership with NIPRO CORPORATION, paving the way for expanding treatment option for patients in Japan ‘NIPRO’ more...
Elevance Health to Hold Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2025 Results on January 28, 2026
INDIANAPOLIS--(BUSINESS WIRE)--Elevance Health (NYSE: ELV) will release fourth quarter and full year 2025 financial results on January 28, 2026, at 6:00 a.m. Eastern Standard Time (“EST”). Management will review these results and its outlook during more...
Fulgent Genetics Agrees to Acquire Bako Diagnostics and StrataDx
Proposed acquisition will add new anatomic pathology services, proprietary PCR tests and a national client baseEL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent”), a technology-based company with a well-established laboratory services business and a more...
Gilead Sciences to Present at Upcoming Investor Conference
FOSTER CITY, Calif.--(BUSINESS WIRE)--#GILD--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor conference: J.P. Morgan Healthcare Conference on Monday, January 12, 2026 beginning at 11:15 a.m. Pacific more...
Vertex to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 12
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Dr. Reshma Kewalramani, Chief Executive Officer and President, will present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026, at 5:15 p.m. more...
Bonsai Health Announces Strategic Partnership with the American Academy of Dermatology to Advance AI-Powered Practice Automation
SANTA MONICA, Calif.--(BUSINESS WIRE)--Bonsai Health, the healthcare technology company building an AI platform to automate complex front office workflows, today announced a strategic partnership with the American Academy of Dermatology (AAD), the largest professional organization more...
IntelePeer Agentic AI Trend Report Cites Trust, Day-One Value, Integration, and Analytics as Critical Success Factors in Healthcare Deployments
2026 Outlook: automated Agentic AI workflows will rapidly emerge as business imperatives to meet patient expectations while driving profitability and resilienceDANIA BEACH, Fla.--(BUSINESS WIRE)--IntelePeer today released a new executive outlook report that offers actionable insights more...
Netsmart Strengthens Interoperability Leadership Through CMS Health Technology Ecosystem Pledge
OVERLAND PARK, Kan.--(BUSINESS WIRE)--#CMSAlignedNetwork--Netsmart, an industry-leading provider of healthcare technology solutions and services for community-based care providers, announced its commitment to the Centers for Medicare & Medicaid Services (CMS) Health Tech Ecosystem initiative as a more...
GenSight Biologics Announces Regulatory Authorization for Early Access Treatment with GS010/LUMEVOQ® in Israel
Israel’s Ministry of Health authorizes individual patients early access treatment with GS010/LUMEVOQ®, a candidate gene therapy for the treatment of ND4-LHON. Bilateral injection expected to be performed in Q1 2026. PARIS--(BUSINESS WIRE)--Regulatory News: GenSight Biologics more...
Navigating the $19.3 Billion Medical Device CRO Market, 2025-2035: Mergers and Acquisitions Boost Geographical Consolidation – ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--The "Medical Device CRO Market: Industry Trends and Global Forecasts, Till 2035 - Distribution by Target Therapeutic Area, Scale of Operation, Device Class, Type of Clinical Service Offered, Type of Preclinical Service Offered and more...
Zambon Biotech Announces First Patient Dosed in Phase 3b ADIP Clinical Study of IPX203 in Parkinson’s Disease
CADEMPINO, Switzerland--(BUSINESS WIRE)--#ClinicalTrial--Zambon Biotech, a specialized biotech company part of the Zambon group that aims to build a scientifically robust and commercially viable portfolio of innovative patient-oriented drugs through the scouting, acquisition, licensing and development more...
Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor
First regulatory approval in the world for pimicotinib based on positive data from global Phase 3 MANEUVER study In MANEUVER, pimicotinib significantly improved objective response rate at week 25 (54% vs. 3.2% for placebo), while more...
Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma
TOKYO--(BUSINESS WIRE)--$INCY--Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma more...
Incyte Japan Announces Approval of Zynyz® (retifanlimab) for the First-Line Treatment of Advanced Anal Cancer
TOKYO--(BUSINESS WIRE)--$INCY--Incyte Biosciences Japan G.K. today announced the Japan Ministry of Health, Labour and Welfare (MHLW) approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of advanced squamous more...
DESTINY-Endometrial02 Phase 3 Trial of ENHERTU® Initiated as Adjuvant Therapy in Patients with HER2 Expressing Endometrial Cancer
TOKYO & BASKING RIDGE, N.J.--(BUSINESS WIRE)--The first patient has been dosed in the DESTINY-Endometrial02 phase 3 trial evaluating ENHERTU® (trastuzumab deruxtecan) with or without radiotherapy compared to standard of care chemotherapy with or without radiotherapy more...
ENHERTU® Granted Breakthrough Therapy Designation in the U.S. as Post-Neoadjuvant Therapy for Patients with HER2 Positive Early Breast Cancer
Tenth Breakthrough Therapy Designation for Daiichi Sankyo and AstraZeneca’s ENHERTU with the latest based on DESTINY-Breast05 phase 3 trial results Sixteenth Breakthrough Therapy Designation granted by the FDA across the oncology portfolio of Daiichi Sankyo more...
FDA Approves Genentech’s Lunsumio VELO™ for Subcutaneous Use in Relapsed or Refractory Follicular Lymphoma
– Lunsumio VELO reduces administration time from 2-4 hours to approximately one minute – – Availability of Lunsumio VELO allows treatment aligned to people’s clinical needs and personal preferences – – Approval supported by data more...
GenSight Biologics Announces the Granting of Compassionate Use Authorization (CUA/AAC) for GS010/LUMEVOQ® in France
French medicines agency ANSM has granted authorization for named patient early access program for GS010/LUMEVOQ®, a gene therapy indicated for the treatment of ND4-LHON. PARIS--(BUSINESS WIRE)--Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), more...
Global Healthy Living Foundation Podcast Network Listens Up 63 Percent; YouTube Views Up 97 Percent.
UPPER NYACK, N.Y.--(BUSINESS WIRE)--The Global Healthy Living Foundation (GHLF) reached record global podcast and YouTube participation in 2025 with more than 700,000 podcast listens (up 63%) and 2 million YouTube views (up 97%) compared with more...
FNIH Announces FDA Qualification of First Surrogate Endpoint for Use in Osteoporosis Clinical Trials
Measuring change in bone mineral density, rather than fracture occurrence, promises to speed development of new drugs to treat osteoporosis. FNIH Biomarkers Consortium collaborated with the National Institutes of Health and other public and private more...
Bristol Myers Squibb Announces Agreement with U.S. Government to Improve Affordability and Access to Critical Medicines for Americans
Eliquis® (apixaban), the Nation’s #1 Prescribed Oral Blood Thinner, Soon Available for Free to Medicaid Program Agreement Provides Tariff Relief for a 3-Year Period PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY, “BMS”) today announced an more...
Swisslog Healthcare Appoints Maria Garces as Vice President of Product Management
Healthcare technology veteran brings extensive product leadership experience BROOMFIELD, Colo.--(BUSINESS WIRE)--Swisslog Healthcare, a leading supplier of transport and pharmacy automation solutions, announces the appointment of Maria Garces as Vice President of Product Management. Garces brings more...
Merck Reaches Agreement With U.S. Government to Expand Access to Medicines and Lower Costs for Americans
Enlicitide has potential to be first approved oral PCSK9 inhibitor designed to help meet critical unmet needs for patients and will be offered at an affordable price to eligible Americans through a direct-to-patient program Merck more...
Gilead and U.S. Government Enter Agreement to Lower Costs of Medicines for Americans
Agreement addresses all requests by President Trump to reduce drug costs in the U.S., encourage global investment and protect American biopharma leadership Company reinforces commitment to U.S. manufacturing and American jobs FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead more...
Von Willebrand Disease Treatment Market Worth $1.75 Billion by 2032: Industry Assessment, Regional Outlook, Competition Benchmarks – ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--The "Von Willebrand Disease Treatment Market - Global Forecast 2025-2032" report has been added to ResearchAndMarkets.com's offering. Senior executives navigating the rare disease pharmaceutical sector require robust, reliable insights to address shifting patient demands, more...